Drew Weissman, MD, PhD is a pioneer of mRNA technology, which has been used in more than 1 billion administered doses of COVID-19 vaccines. Weissman is the Roberts Family Professor in Vaccine Research, Director of Vaccine Research in the Infectious Disease Division, and the Director of the Institute for RNA Innovation at the University of Pennsylvania and the Perelman School of Medicine.

He co-developed the mRNA technology that made the COVID-19 vaccines possible. His inventions were used in the Pfizer and Moderna vaccines, and have the potential to treat a range of medical conditions. He is also promoting global vaccine access by working with governments and universities around the world.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Drew Weissman, MD, PhD is a pioneer of mRNA technology, which has been used in more than 1 billion administered doses of COVID-19 vaccines. Weissman is the Roberts Family Professor in Vaccine Research, Director of Vaccine Research in the Infectious Disease Division, and the Director of the Institute for RNA Innovation at the University of Pennsylvania and the Perelman School of Medicine.
He co-developed the mRNA technology that made the COVID-19 vaccines possible. His inventions were used in the Pfizer and Moderna vaccines, and have the potential to treat a range of medical conditions. He is also promoting global vaccine access by working with governments and universities around the world.
Music by: Steven O'Brien <a href="https://protect-us.mimecast.com/s/jcayCv2rxWtyKRVTQLe7p">https://www.steven-obrien.net/</a>
"Making Progress"
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/ibdECwpvyXUR92rIq1jwO">https://creativecommons.org/licenses/by/4.0/</a>)

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

ASGCT Podcast Network

04 - Drew Weissman, MD, PhD - Giants of Gene Therapy

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Los Angeles.

Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more!

Looking for a curated guide through the Annual Meeting? Check out ASGCT's new Session Paths! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles:
First-time Attendees
Cancer
Clinical Science
Gene Editing
Regulatory + Government Affairs
Viral Vectors

There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit https://annualmeeting.asgct.org/register to learn more and register today.

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Los Angeles.
Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more!
Looking for a curated guide through the Annual Meeting? Check out ASGCT's new <a href="https://annualmeeting.asgct.org/session-paths">Session Paths</a>! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles:
<ul>
<li>First-time Attendees</li>
<li>Cancer</li>
<li>Clinical Science</li>
<li>Gene Editing</li>
<li>Regulatory + Government Affairs</li>
<li>Viral Vectors</li>
</ul>
There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit <a href="https://annualmeeting.asgct.org/register">https://annualmeeting.asgct.org/register</a> to learn more and register today.

ASGCT 2024 Abstract Highlights with Chris Leidli, Emily Walsh Martin, and Lynnea Olivarez

Tune in for an exceptional discussion on chemistry, manufacturing, and controls with Dr. Susan D’Costa, Chief Technical and Commercial Officer at Genezen, a US-based CDMO for viral vectors. "Geek out" with Susan and Emily on the intricacies of defining your CMC strategy and ready yourselves for a tour-de-force of analytical and process development for viral vectors.

The future of cell and gene therapy is nearly here! The ASGCT Annual Meeting is less than a month away, and starting on April 22, you can download the abstracts collection to get a sneak peek at the cutting-edge research being presented May 7-11 in Baltimore.

Explore the latest breakthroughs and discoveries shaping the field, and don't miss the premier event in cell and gene therapy. Visit www.annualmeeting.asgct.org to learn more and register today!

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Tune in for an exceptional discussion on chemistry, manufacturing, and controls with Dr. Susan D’Costa, Chief Technical and Commercial Officer at Genezen, a US-based CDMO for viral vectors. "Geek out" with Susan and Emily on the intricacies of defining your CMC strategy and ready yourselves for a tour-de-force of analytical and process development for viral vectors.
The future of cell and gene therapy is nearly here! The ASGCT Annual Meeting is less than a month away, and starting on April 22, you can download the abstracts collection to get a sneak peek at the cutting-edge research being presented May 7-11 in Baltimore.
Explore the latest breakthroughs and discoveries shaping the field, and don't miss the premier event in cell and gene therapy. Visit <a href="http://www.annualmeeting.asgct.org">www.annualmeeting.asgct.org</a> to learn more and register today!
Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a> -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)

CMC Strategy with Susan D'Costa, PhD—The Issue

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.

Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children’s Hospital

Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center

Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals

ASGCT members save $385 on registration rates for the ASGCT Annual Meeting whether you’re attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org.

'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children’s Hospital
Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center
Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals
ASGCT members save $385 on registration rates for the ASGCT <a href="https://annualmeeting.asgct.org/">Annual Meeting</a> whether you’re attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at <a href="https://annualmeeting.asgct.org/">annualmeeting.asgct.org</a>.
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. <a href="https://protect-us.mimecast.com/s/CXOTCL9w1QUXqP0HBBFDP">www.scottbuckley.com.au</a>

04 - Drew Weissman, MD, PhD - Giants of Gene Therapy

In 1 playlist(s)

ASGCT Podcast Network

Social links

Follow podcast

Recent clips